AEON Logo

AEON Biopharma, Inc. (AEON) Stock Forecast & Price Prediction

Live AEON Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NYSE | Healthcare | Biotechnology

$0.13

0.00 (-0.08%)

12 Month Price Forecast For AEON

$0.13
Current Price
$10.39M
Market Cap
1 Ratings
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to AEON Price Forecasts

+3,749.1%
To High Target of $5.00
+3,749.1%
To Median Target of $5.00
+3,749.1%
To Low Target of $5.00

AEON Price Momentum

+8.3%
1 Week Change
-31.6%
1 Month Change
-98.6%
1 Year Change
-75.9%
Year-to-Date Change
-99.2%
From 52W High of $17.17
+28.6%
From 52W Low of $0.10

๐Ÿค” Considering AEON Biopharma (AEON)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 11, 2025 5:38 PM UTC

AEON Analyst Ratings & Price Targets

Based on our analysis of 1 Wall Street analyst, AEON has a bullish consensus with a median price target of $5.00 (ranging from $5.00 to $5.00). Currently trading at $0.13, the median forecast implies a 3,749.1% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Douglas Tsao at HC Wainwright & Co., projecting a 3,749.1% upside. Conversely, the most conservative target is provided by Douglas Tsao at HC Wainwright & Co., suggesting a 3,749.1% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

AEON Analyst Consensus

1
Buy
0
Hold
0
Sell

AEON Price Target Range

Low
$5.00
Average
$5.00
High
$5.00
Current: $0.13

Latest AEON Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for AEON.

Date Firm Analyst Rating Change Price Target
Oct 1, 2024 HC Wainwright & Co. Douglas Tsao Buy Reiterates $5.00
Aug 14, 2024 HC Wainwright & Co. Douglas Tsao Buy Maintains $5.00
Jul 10, 2024 HC Wainwright & Co. Douglas Tsao Buy Reiterates $6.00
May 30, 2024 HC Wainwright & Co. Douglas Tsao Buy Reiterates $6.00
May 15, 2024 HC Wainwright & Co. Douglas Tsao Buy Maintains $6.00
May 6, 2024 HC Wainwright & Co. Douglas Tsao Buy Reiterates $18.00
Apr 17, 2024 HC Wainwright & Co. Douglas Tsao Buy Reiterates $18.00
Aug 18, 2023 HC Wainwright & Co. Douglas Tsao Buy Initiates $18.00

Stocks Similar to AEON Biopharma, Inc.

The following stocks are similar to AEON Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

AEON Biopharma, Inc. (AEON) Financial Data

AEON Biopharma, Inc. has a market capitalization of $10.39M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of N/A.

Valuation Metrics

Market Cap $10.39M
Enterprise Value $32.96M
P/E Ratio 0.0x
PEG Ratio -0.2x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +67.0%
Current Ratio 0.4x
Debt/Equity -0.5x
ROE N/A
ROA -597.7%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

AEON Biopharma, Inc. logo

AEON Biopharma, Inc. (AEON) Company Overview

About AEON Biopharma, Inc.

What They Do

Develops botulinum toxins for medical conditions.

Business Model

AEON Biopharma operates as a clinical stage biopharmaceutical company, focusing on the development of botulinum toxins. The company generates revenue by advancing its drug candidates through clinical trials, with potential future income from product sales upon successful commercialization.

Additional Information

The company's lead product, ABP-450, has completed a Phase 2 study for cervical dystonia and is currently in ongoing trials for chronic and episodic migraine, as well as other conditions like gastroparesis and PTSD. AEON Biopharma is headquartered in Irvine, California.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

5

CEO

Mr. Marc Forth

Country

United States

IPO Year

2023

AEON Biopharma, Inc. (AEON) Latest News & Analysis

AEON stock latest news image
Quick Summary

AEON Biopharma, Inc. received a notice from NYSE American for non-compliance with equity requirements due to a $32.1 million stockholders' deficit and reported losses in recent fiscal years.

Why It Matters

AEON Biopharma's non-compliance with NYSE American's equity requirements raises concerns about its financial health, potentially impacting stock value and investor confidence.

Source: GlobeNewsWire
Market Sentiment: Neutral
AEON stock latest news image
Quick Summary

AEON Biopharma, Inc. closed a public offering on January 7, 2025, raising approximately $20 million before expenses. The company focuses on developing a botulinum toxin complex under a biosimilar pathway.

Why It Matters

AEON Biopharma's $20 million public offering enhances its financial position, potentially accelerating research and development, which could drive future growth and impact stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
AEON stock latest news image
Quick Summary

AEON Biopharma, Inc. (NYSE: AEON) has launched a public offering of units, which include shares of Common Stock and warrants to purchase Common Stock, as part of its biosimilar development strategy.

Why It Matters

AEON Biopharma's public offering can dilute existing shares and signal capital needs, impacting stock price and investor sentiment. Its focus on a biosimilar pathway may attract interest in biotech growth potential.

Source: GlobeNewsWire
Market Sentiment: Neutral
AEON stock latest news image
Quick Summary

The company held a biosimilar advisory meeting with the FDA in Q3 2024, aligning on a 351(k) regulatory pathway for ABP-450 as a biosimilar to BOTOXยฎ.

Why It Matters

Progress in the regulatory pathway for ABP-450 as a biosimilar to BOTOXยฎ could lead to market entry, potentially increasing revenue and market share for the company involved.

Source: GlobeNewsWire
Market Sentiment: Neutral
AEON stock latest news image
Quick Summary

AEON Biopharma, Inc. shows a hammer chart pattern signaling support after recent losses, alongside rising earnings estimate revisions, suggesting a potential trend reversal.

Why It Matters

The hammer pattern signals potential support for AEON's stock, while rising earnings estimates suggest a possible trend reversal, indicating a favorable outlook for investors.

Source: Zacks Investment Research
Market Sentiment: Positive
AEON stock latest news image
Quick Summary

AEON Biopharma, Inc. (NYSE: AEON) will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, at 1:30 PM ET.

Why It Matters

AEON Biopharma's CEO presentation at a major investment conference may highlight key developments and attract investor interest, potentially impacting stock performance and market perception.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About AEON Stock

What is AEON Biopharma, Inc.'s (AEON) stock forecast for 2025?

Based on our analysis of 1 Wall Street analysts, AEON Biopharma, Inc. (AEON) has a median price target of $5.00. The highest price target is $5.00 and the lowest is $5.00.

Is AEON stock a good investment in 2025?

According to current analyst ratings, AEON has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.13. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for AEON stock?

Wall Street analysts predict AEON stock could reach $5.00 in the next 12 months. This represents a 3,749.1% increase from the current price of $0.13. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is AEON Biopharma, Inc.'s business model?

AEON Biopharma operates as a clinical stage biopharmaceutical company, focusing on the development of botulinum toxins. The company generates revenue by advancing its drug candidates through clinical trials, with potential future income from product sales upon successful commercialization.

What is the highest forecasted price for AEON AEON Biopharma, Inc.?

The highest price target for AEON is $5.00 from Douglas Tsao at HC Wainwright & Co., which represents a 3,749.1% increase from the current price of $0.13.

What is the lowest forecasted price for AEON AEON Biopharma, Inc.?

The lowest price target for AEON is $5.00 from Douglas Tsao at HC Wainwright & Co., which represents a 3,749.1% increase from the current price of $0.13.

What is the overall AEON consensus from analysts for AEON Biopharma, Inc.?

The overall analyst consensus for AEON is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.00.

How accurate are AEON stock price projections?

Stock price projections, including those for AEON Biopharma, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.